Alpibectir plus Ethionamide OD

Phase 2Small molecule

TTASK Applied Science

Alpibectir plus Ethionamide OD is one of 5 small molecule programs targeting Acceptability. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcceptabilityRecruiting

AcceptabilityPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Acceptability

#DrugCompanyPhaseTrials

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Phase 3

3 2

Mifeprex

DDanco

Phase 3

2 3

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

1 4

Alpibectir plus Ethionamide OD

TTASK Applied Science

Phase 2

1 5

Nuvaring

UUniversity of Washington

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acceptability1 trial

A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

Recruiting·TTASK Applied Science·Phase 2·NCT06748937·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alpibectir plus Ethionamide OD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpibectir plus Ethionamide OD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpibectir plus Ethionamide OD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TASK Applied Science company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTASK Applied Science

Alpibectir plus Ethionamide OD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acceptability1 trial

References

Drug Info

Quick Facts

Related News